# Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

> **NCT00998738** · PHASE3 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 1 (actual)

## Conditions studied

- Neuropathy
- Pain
- Recurrent Breast Carcinoma
- Stage IV Breast Cancer

## Interventions

- **DRUG:** Calcium Gluconate
- **DRUG:** Magnesium Sulfate
- **OTHER:** Placebo
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Ixabepilone

## Key facts

- **NCT ID:** NCT00998738
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2010-07
- **Final completion:** 2013-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** lack of accrual
- **Last updated:** 2016-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00998738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00998738, "Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00998738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*